Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

Detalhes bibliográficos
Autor(a) principal: Jarimba, Roberto Saldanha
Data de Publicação: 2021
Outros Autores: Eliseu, Miguel Nobre, Pedroso Lima, João, Quaresma, Vasco, Moreira, Pedro, Nunes, Pedro Coelho, Silva, Edgar Tavares da, Figueiredo, Arnaldo José
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/100893
https://doi.org/10.4081/aiua.2021.4.393
Resumo: Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.
id RCAP_68a68d56b4f5ac05a245632bf90d89ba
oai_identifier_str oai:estudogeral.uc.pt:10316/100893
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective studyProstate cancerAbirateroneEnzalutamideCastration-resistantAbiraterone AcetateHumansMaleProspective StudiesRetrospective StudiesTreatment OutcomeAntineoplastic AgentsProstatic Neoplasms, Castration-ResistantProstate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.2021-12-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/100893http://hdl.handle.net/10316/100893https://doi.org/10.4081/aiua.2021.4.393eng2282-41971124-3562Jarimba, Roberto SaldanhaEliseu, Miguel NobrePedroso Lima, JoãoQuaresma, VascoMoreira, PedroNunes, Pedro CoelhoSilva, Edgar Tavares daFigueiredo, Arnaldo Joséinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-07-19T20:37:52Zoai:estudogeral.uc.pt:10316/100893Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:18:11.125893Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
spellingShingle Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
Jarimba, Roberto Saldanha
Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
title_short Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_full Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_fullStr Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_full_unstemmed Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_sort Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
author Jarimba, Roberto Saldanha
author_facet Jarimba, Roberto Saldanha
Eliseu, Miguel Nobre
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
Silva, Edgar Tavares da
Figueiredo, Arnaldo José
author_role author
author2 Eliseu, Miguel Nobre
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
Silva, Edgar Tavares da
Figueiredo, Arnaldo José
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Jarimba, Roberto Saldanha
Eliseu, Miguel Nobre
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
Silva, Edgar Tavares da
Figueiredo, Arnaldo José
dc.subject.por.fl_str_mv Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
topic Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
description Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-20
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/100893
http://hdl.handle.net/10316/100893
https://doi.org/10.4081/aiua.2021.4.393
url http://hdl.handle.net/10316/100893
https://doi.org/10.4081/aiua.2021.4.393
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2282-4197
1124-3562
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134076899164160

Registros relacionados